Wellington Management Group LLP Sells 47,776 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Wellington Management Group LLP reduced its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 25.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 138,136 shares of the company’s stock after selling 47,776 shares during the quarter. Wellington Management Group LLP’s holdings in Teva Pharmaceutical Industries were worth $2,123,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of TEVA. Stifel Financial Corp grew its stake in shares of Teva Pharmaceutical Industries by 33.3% during the fourth quarter. Stifel Financial Corp now owns 88,478 shares of the company’s stock valued at $1,950,000 after buying an additional 22,087 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Teva Pharmaceutical Industries by 18.7% in the fourth quarter. The Manufacturers Life Insurance Company now owns 513,328 shares of the company’s stock worth $11,314,000 after purchasing an additional 80,926 shares during the last quarter. Northern Trust Corp grew its stake in shares of Teva Pharmaceutical Industries by 69.0% in the fourth quarter. Northern Trust Corp now owns 5,206,360 shares of the company’s stock worth $114,748,000 after purchasing an additional 2,125,266 shares during the last quarter. Alyeska Investment Group L.P. grew its stake in shares of Teva Pharmaceutical Industries by 0.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 3,641,392 shares of the company’s stock worth $80,256,000 after purchasing an additional 16,392 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Teva Pharmaceutical Industries by 3.9% in the fourth quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company’s stock worth $3,254,000 after purchasing an additional 5,494 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,001 shares of company stock worth $996,958. Insiders own 0.49% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several recent analyst reports. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Bank of America raised their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 target price on the stock. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, UBS Group cut their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $18.41 on Friday. The stock’s 50 day simple moving average is $16.86 and its two-hundred day simple moving average is $16.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The stock has a market cap of $21.11 billion, a price-to-earnings ratio of -115.04, a PEG ratio of 1.09 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business’s revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.